These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 20849311)

  • 1. Pretherapy prediction of nephrotoxicity after peptide radionuclide receptor therapy (PRRT).
    Denardo GL; Macey DJ
    Cancer Biother Radiopharm; 2010 Oct; 25(5):507-9. PubMed ID: 20849311
    [No Abstract]   [Full Text] [Related]  

  • 2. Dosimetry in Peptide radionuclide receptor therapy: a review.
    Cremonesi M; Ferrari M; Bodei L; Tosi G; Paganelli G
    J Nucl Med; 2006 Sep; 47(9):1467-75. PubMed ID: 16954555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal dosimetry in peptide radionuclide receptor therapy.
    Siegel JA; Stabin MG; Sharkey RM
    Cancer Biother Radiopharm; 2010 Oct; 25(5):581-8. PubMed ID: 20849308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update: improvement strategies for peptide receptor scintigraphy and radionuclide therapy.
    de Visser M; Verwijnen SM; de Jong M
    Cancer Biother Radiopharm; 2008 Apr; 23(2):137-57. PubMed ID: 18454684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of gastroenteropancreatic neuroendocrine tumors with peptide receptor radionuclide therapy.
    van Vliet EI; Teunissen JJ; Kam BL; de Jong M; Krenning EP; Kwekkeboom DJ
    Neuroendocrinology; 2013; 97(1):74-85. PubMed ID: 22237390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Candidates for peptide receptor radiotherapy today and in the future.
    Reubi JC; Mäcke HR; Krenning EP
    J Nucl Med; 2005 Jan; 46 Suppl 1():67S-75S. PubMed ID: 15653654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent issues on dosimetry and radiobiology for peptide receptor radionuclide therapy.
    Cremonesi M; Ferrari M; Di Dia A; Botta F; De Cicco C; Bodei L; Paganelli G
    Q J Nucl Med Mol Imaging; 2011 Apr; 55(2):155-67. PubMed ID: 21386788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptide receptor radionuclide therapy: an overview.
    Dash A; Chakraborty S; Pillai MR; Knapp FF
    Cancer Biother Radiopharm; 2015 Mar; 30(2):47-71. PubMed ID: 25710506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Introduction to kidney dose-response for radionuclide therapy.
    Sgouros G
    Cancer Biother Radiopharm; 2004 Jun; 19(3):357-8. PubMed ID: 15285882
    [No Abstract]   [Full Text] [Related]  

  • 10. Nephrotoxicity versus anti-tumour efficacy in radiopeptide therapy: facts and myths about the Scylla and Charybdis.
    Behr TM; Béhé M; Kluge G; Gotthardt M; Schipper ML; Gratz S; Arnold R; Becker W; Goldenberg DM
    Eur J Nucl Med Mol Imaging; 2002 Feb; 29(2):277-9. PubMed ID: 11926391
    [No Abstract]   [Full Text] [Related]  

  • 11. Preclinical and clinical studies of peptide receptor radionuclide therapy.
    Pool SE; Krenning EP; Koning GA; van Eijck CH; Teunissen JJ; Kam B; Valkema R; Kwekkeboom DJ; de Jong M
    Semin Nucl Med; 2010 May; 40(3):209-18. PubMed ID: 20350630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic and locoregional dosimetry in receptor radionuclide therapy with peptides.
    Cremonesi M; Ferrari M; Bodei L; Tosi G; Paganelli G
    Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):288-95. PubMed ID: 17043626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of dose with toxicity and tumour response to
    Cremonesi M; Ferrari ME; Bodei L; Chiesa C; Sarnelli A; Garibaldi C; Pacilio M; Strigari L; Summers PE; Orecchia R; Grana CM; Botta F
    Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2426-2441. PubMed ID: 29785514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptide-based radiopharmaceuticals for targeted tumor therapy.
    Dong C; Liu Z; Wang F
    Curr Med Chem; 2014; 21(1):139-52. PubMed ID: 23992337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in Peptide Receptor Radionuclide Therapy.
    Sabet A; Biersack HJ; Ezziddin S
    Semin Nucl Med; 2016 Jan; 46(1):40-6. PubMed ID: 26687856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues.
    Bodei L; Pepe G; Paganelli G
    Eur Rev Med Pharmacol Sci; 2010 Apr; 14(4):347-51. PubMed ID: 20496546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal and Red Marrow Dosimetry in Peptide Receptor Radionuclide Therapy: 20 Years of History and Ahead.
    Walrand S; Jamar F
    Int J Mol Sci; 2021 Aug; 22(15):. PubMed ID: 34361092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential and pitfalls of therapy with alpha-particles.
    Welch MJ
    J Nucl Med; 2005 Aug; 46(8):1254-5. PubMed ID: 16085579
    [No Abstract]   [Full Text] [Related]  

  • 19. Endoradiotherapy in cancer treatment--basic concepts and future trends.
    Zoller F; Eisenhut M; Haberkorn U; Mier W
    Eur J Pharmacol; 2009 Dec; 625(1-3):55-62. PubMed ID: 19836381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receptor-mediated tumor targeting with radiolabeled peptides: there is more to it than somatostatin analogs.
    Mariani G; Erba PA; Signore A
    J Nucl Med; 2006 Dec; 47(12):1904-7. PubMed ID: 17138731
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.